[Cervical cancer screening : implementation of the hr-HPV test]

Cervical cancer remains the fourth most common cancer in women. Recognition of the involvement of viral infection by human papillomavirus (HPV) in the carcinogenesis of lesions has enabled the evolution and adaptation of screening methods. Early detection of pre-invasive lesions and their treatment ultimately led to a reduction in the incidence and mortality of cervical cancer. In Belgium, the transition to primary screening is validated since January 1st, 2025. Let us nevertheless remember the importance of primary prevention through recommended vaccination for girls and boys.